Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

Alex1m2 Feb. 23 at 3:59 PM

$FBIOP When should we expect dividend reinstatement?

0 · Reply

Sawnchey Feb. 23 at 2:44 PM

$FBIO $FBIOP Below is the segment report from the latest 10-Q published November 14th. On that day the stock price was 2.62. In the 10-Q to be published in May: the following is likely to be different: 1: The Pink Highlight is likely to be a profit, rather than a loss. 2: The Yellow Highlight will likely be somewhere in the rigion of 140 Million dollars. 3: The Green Highlight will likely have a number above 100 Million dollars. So +50% on the common stock since then doesn’t sound like the correct number!

0 · Reply

FinSUN Feb. 23 at 1:58 PM

$FBIOP Back to $19.

1 · Reply

FinSUN Feb. 23 at 1:56 PM

$FBIOP

0 · Reply

Sawnchey Feb. 23 at 1:48 PM

$FBIO $FBIOP Some quick and dirty maths: 205m minus obligations (Cyprium Preferred repurchase, NIH, repayment of Oaktree Notes), times 0.74 for fortress proportional pwnership of Cyprium, divided by roughly 33m shares (assuming equality between preferred and common). The interest per share in this PRV is a few cents shy of 4 DOLLARS. If you are able to purchase common stock below this number, then you are getting in below 1x price to book after discounting literally everything except the PRV. This company could not unreasonably be valued in the double digits, compared to the value ratios similar companies enjoy.

0 · Reply

makrodimutross Feb. 20 at 6:33 PM

$FBIO Why? Perhaps the market is assuming management has implied that making good on their arrears to the holders of $FBIOP is not a priority to them at this time. Maybe the market thinks that the management thinks: "Eventually they will get paid, and they should be happy with that". If the market is convinced that this is the attitude management has towards the senior securities holders, what must it think of the attitude management may have towards the common shareholders? I believe some clarity will be delivered in the upcoming annual filing. If there is no expression of insider confidence through form 4s after the blackout period, we may be looking a groundhog afraid of its shadow. Another year of winter for the company.

2 · Reply

makrodimutross Feb. 18 at 7:29 PM

$FBIOP $FBIO I've said it before and I'll say it again: Suspended dividends in FBIOP are an albatross around the neck of this company. ------------------------------------------------------ ...'God save thee, ancient Mariner! From the fiends, that plague thee thus!— Why look'st thou so?'—With my cross-bow I shot the ALBATROSS... ... ...O happy living things! no tongue Their beauty might declare: A spring of love gushed from my heart, And I blessed them unaware: Sure my kind saint took pity on me, And I blessed them unaware. The self-same moment I could pray; And from my neck so free The Albatross fell off, and sank Like lead into the sea.

2 · Reply

makrodimutross Feb. 17 at 9:05 PM

$FBIOP $FBIO It's nice to not feel so alone. This is an excellent anaylisis, done with a sober-minded understanding of the multiple paths forward for both Cyprium and Fortress: https://suspendedjoey.substack.com/p/special-sits-in-fortress-biotech?utm_source=share&utm_medium=android&r=40id8&triedRedirect=true

3 · Reply

FinSUN Feb. 11 at 11:12 PM

$FBIOP and they shouldn't. I am here opportunistically only. I don't trust the management at all.

1 · Reply

makrodimutross Feb. 11 at 10:19 PM

$FBIOP $FBIO FBIOP is now trading at approximately 38% of it's liquidation preference + arrears. Either the common shares are currently overvalued, or the preferred shares are Severely undervalued. Either way, it appears the market still doesn't trust this company until the money is in the bank. Even the Sun Pharma deal wasn't enough to bring CKPT to cash value. The market waited until the deal was literally inked before the shares reached fmv.

1 · Reply